Results 81 to 90 of about 2,667 (188)
Nephrology, Volume 31, Issue 2, February 2026.ABSTRACT IgA nephropathy is a progressive glomerular disease with a variable clinical course and a substantial risk of progression to end‐stage kidney failure. While proteinuria has long been the central therapeutic target, insights into disease pathogenesis indicate that haematuria should also guide treatment decisions. Based on the pathophysiology of
Yusuke Suzuki
wiley +1 more source
Delayed‐Onset Hemolysis in a Case of Hemolytic Uremic Syndrome: A Diagnostic Challenge
Case Reports in Hematology, Volume 2026, Issue 1, 2026.Background Hemolytic uremic syndrome is a rare thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury. While commonly reported in children, adult‐onset presentations are less frequent and often atypical, leading to diagnostic delays.
Muhammad Younas +4 more
wiley +1 more source
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
Therapeutic Advances in Hematology, 2019 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj +1 more source
Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience [PDF]
Introduction: Thymoma-associated myasthenia gravis (TAMG) accounts for 15-20% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal response to conventional therapies.
Erra, Carmen +6 more
core +1 more source
Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.Background Ravulizumab represents the inaugural long‐acting complement C5 inhibitor that has received approval in various countries around the globe for individuals diagnosed with generalized myasthenia gravis (gMG) who are positive for anti‐acetylcholine receptor antibodies.
Yakun Wang +5 more
wiley +1 more source
Examining Consistency Across NICE Single Technology Appraisals:A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria [PDF]
In 2024, the National Institute for Health and Care Excellence (NICE) recommended two new health technologies for paroxysmal nocturnal haemoglobinuria. This review systematically compares the clinical and cost-effectiveness evidence considered within the
Donoghue, Jeremiah +6 more
core +1 more source
Therapeutics and Clinical Risk Management, 2021 Carmelo Gurnari,1,2 Ishani Nautiyal,1 Simona Pagliuca1,3 1Department of Translational Hematology and Oncology Research, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Biomedicine and Prevention, PhD in Immunology ...
Gurnari C, Nautiyal I, Pagliuca S
doaj
Frontiers in Immunology, 2019 The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
Antonio M. Risitano +15 more
doaj +1 more source
Journal of Comparative Effectiveness ResearchThis summary gives an overview of three published articles that report the results of research studies of ravulizumab, an approved treatment for people with atypical hemolytic uremic syndrome (often shortened to aHUS).
Michal Nowicki, Nikoleta Printza
doaj +1 more source